Moreover, pro-tumorigenic triggers are enhanced by the expression of FasL on tumor endothelial cells, which in turn, inhibits the proliferation of TCD8+ effector cells’ bed, allowing tumor spreading and resistance to anti-cancer treatment [35,36,37]. This evidence concerns the gene FASLG and neoplasm.